Loading...
XASX
NTI
Market cap12mUSD
Dec 05, Last price  
0.02AUD
1D
5.88%
1Q
28.57%
Jan 2017
-94.66%
IPO
-93.14%
Name

Neurotech International Ltd

Chart & Performance

D1W1MN
XASX:NTI chart
P/E
P/S
9,624.65
EPS
Div Yield, %
Shrs. gr., 5y
50.45%
Rev. gr., 5y
-60.12%
Revenues
2k
-67.06%
126,66788,31030,047194,55677,366206,14438,2625,9591,963
Net income
-5m
L-34.94%
-2,181,346-4,031,790-3,990,293-4,802,208-1,713,439-7,430,628-3,362,241-7,791,939-5,069,251
CFO
-5m
L-27.25%
-785,786-3,120,973-3,025,662-2,543,052-682,831-2,316,528-2,955,134-6,316,955-4,595,291

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Neurotech International Limited, together with its subsidiaries, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company is focused on development and commercializing Mente platform, a platform technology to monitor and play role in home-based therapies. Its product includes Mente Autism for the diagnosis and treatment of autism. It also engages in executing of medical research projects; and developing of technological devices. The company was incorporated in 2016 and is based in Nedlands, Australia.
IPO date
Nov 04, 2016
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT